Breaking News
IT'S OVER: Banks Tap Fed for $17 BILLION as Silver Shorts Implode
SEMI-NEWS/SEMI-SATIRE: December 28, 2025 Edition
China Will Close the Semiconductor Gap After EUV Lithography Breakthrough
The Five Big Lies of Vaccinology
Top Tech News
EngineAI T800: Born to Disrupt! #EngineAI #robotics #newtechnology #newproduct
This Silicon Anode Breakthrough Could Mark A Turning Point For EV Batteries [Update]
Travel gadget promises to dry and iron your clothes – totally hands-free
Perfect Aircrete, Kitchen Ingredients.
Futuristic pixel-raising display lets you feel what's onscreen
Cutting-Edge Facility Generates Pure Water and Hydrogen Fuel from Seawater for Mere Pennies
This tiny dev board is packed with features for ambitious makers
Scientists Discover Gel to Regrow Tooth Enamel
Vitamin C and Dandelion Root Killing Cancer Cells -- as Former CDC Director Calls for COVID-19...
Galactic Brain: US firm plans space-based data centers, power grid to challenge China
Oligodendrocyte progenitor cells repair damaged spine in humans in clinical trial...
AST's technology comes from one of the leading companies in regenerative medicine, BioTime, Inc., (NYSE: BTX) which spun off Asterias Biotherapeutics a few years ago and is also its largest shareholder. It is also worth pointing out that BioTime's CEO, Dr. Michael West, is one of the world's leading experts in regenerative and stem cell research
Asterias Biotherapeutics is a leading biotechnology company in the emerging field of regenerative medicine. The company's proprietary cell therapy programs are based on its immunotherapy and pluripotent stem cell platform technologies. Asterias is presently focused on advancing three clinical-stage programs which have the potential to address areas of very high unmet medical need in the fields of oncology and neurology.
Dr Michael West will use regenerative stem cell medicine to solve the primary diseases of aging.